Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rogier Versteeg

Showing results (91-100 of 139) with videos related to

Pageof 14
Sort By:
Nature|March 22, 2019
Recruitment of BRCA1 limits MYCN-driven accumulation of stalled RNA polymeraseSteffi Herold, Jacqueline Kalb, Gabriele Büchel, et al.
JCI Insight|August 9, 2022
DHODH is an independent prognostic marker and potent therapeutic target in neuroblastomaThale Kristin Olsen, Cecilia Dyberg, Bethel Tesfai Embaie, et al.
Molecular and Cellular Biology|February 13, 2008
Genome-wide pattern of TCF7L2/TCF4 chromatin occupancy in colorectal cancer cellsPantelis Hatzis, Laurens G van der Flier, Marc A van Driel, et al.
Genes & Development|April 18, 2025
The USP11/TCEAL1 complex promotes transcription elongation to sustain oncogenic gene expression in neuroblastomaMarkus Dehmer, Katrin Trunk, Peter Gallant, et al.
Genes, Chromosomes & Cancer|September 8, 2007
ArrayCGH-based classification of neuroblastoma into genomic subgroupsEvi Michels, Jo Vandesompele, Katleen De Preter, et al.
Oncotarget|June 9, 2015
Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanismStefano J Mandriota, Linda J Valentijn, Laurence Lesne, et al.
Plos One|September 5, 2008
Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological featuresMarcel Kool, Jan Koster, Jens Bunt, et al.
International Journal of Cancer|July 29, 2011
Identification of a novel recurrent 1q42.2-1qter deletion in high risk MYCN single copy 11q deleted neuroblastomasAnnelies Fieuw, Candy Kumps, Alexander Schramm, et al.
Cancer Cell|October 4, 2016
Glycerophosphodiesterase GDE2 Promotes Neuroblastoma Differentiation through Glypican Release and Is a Marker of Clinical OutcomeElisa Matas-Rico, Michiel van Veen, Daniela Leyton-Puig, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2015
Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent NeuroblastomaM Emmy M Dolman, Evon Poon, Marli E Ebus, et al.
Pageof 14

Showing results (91-100 of 139) with videos related to

Sort By:
Pageof 14
Nature|March 22, 2019
Recruitment of BRCA1 limits MYCN-driven accumulation of stalled RNA polymeraseSteffi Herold, Jacqueline Kalb, Gabriele Büchel, et al.
JCI Insight|August 9, 2022
DHODH is an independent prognostic marker and potent therapeutic target in neuroblastomaThale Kristin Olsen, Cecilia Dyberg, Bethel Tesfai Embaie, et al.
Molecular and Cellular Biology|February 13, 2008
Genome-wide pattern of TCF7L2/TCF4 chromatin occupancy in colorectal cancer cellsPantelis Hatzis, Laurens G van der Flier, Marc A van Driel, et al.
Genes & Development|April 18, 2025
The USP11/TCEAL1 complex promotes transcription elongation to sustain oncogenic gene expression in neuroblastomaMarkus Dehmer, Katrin Trunk, Peter Gallant, et al.
Genes, Chromosomes & Cancer|September 8, 2007
ArrayCGH-based classification of neuroblastoma into genomic subgroupsEvi Michels, Jo Vandesompele, Katleen De Preter, et al.
Oncotarget|June 9, 2015
Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanismStefano J Mandriota, Linda J Valentijn, Laurence Lesne, et al.
Plos One|September 5, 2008
Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological featuresMarcel Kool, Jan Koster, Jens Bunt, et al.
International Journal of Cancer|July 29, 2011
Identification of a novel recurrent 1q42.2-1qter deletion in high risk MYCN single copy 11q deleted neuroblastomasAnnelies Fieuw, Candy Kumps, Alexander Schramm, et al.
Cancer Cell|October 4, 2016
Glycerophosphodiesterase GDE2 Promotes Neuroblastoma Differentiation through Glypican Release and Is a Marker of Clinical OutcomeElisa Matas-Rico, Michiel van Veen, Daniela Leyton-Puig, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2015
Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent NeuroblastomaM Emmy M Dolman, Evon Poon, Marli E Ebus, et al.
Pageof 14